Galectin Therapeutics Files 8-K

Ticker: GALT · Form: 8-K · Filed: Sep 9, 2024 · CIK: 1133416

Galectin Therapeutics INC 8-K Filing Summary
FieldDetail
CompanyGalectin Therapeutics INC (GALT)
Form Type8-K
Filed DateSep 9, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, corporate-filing, financials

TL;DR

GALECTIN THERAPEUTICS INC. filed an 8-K on 9/9/24. Standard reporting.

AI Summary

Galectin Therapeutics Inc. filed an 8-K on September 9, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Pro Pharmaceuticals Inc., is incorporated in Nevada and headquartered in Norcross, Georgia.

Why It Matters

This filing indicates routine corporate reporting, including financial statements and potential disclosures relevant to investors.

Risk Assessment

Risk Level: low — This filing appears to be a routine corporate disclosure and does not immediately suggest significant new risks.

Key Numbers

Key Players & Entities

FAQ

What specific events or information are being disclosed in this 8-K filing?

The filing indicates it pertains to Regulation FD Disclosure and Financial Statements and Exhibits, but the specific details of these disclosures are not provided in the excerpt.

When was Galectin Therapeutics Inc. previously known by another name?

The company was formerly known as Pro Pharmaceuticals Inc., with a date of name change on June 12, 2001.

Where is Galectin Therapeutics Inc. headquartered?

The company's principal executive office is located at 4960 Peachtree Industrial Boulevard, Suite 240, Norcross, GA 30071.

In which state is Galectin Therapeutics Inc. incorporated?

Galectin Therapeutics Inc. is incorporated in Nevada.

What is the filing date for this 8-K report?

The report was filed as of September 9, 2024.

Filing Stats: 620 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-09-09 08:00:45

Key Financial Figures

Filing Documents

01

Item 7.01 Regulation FD Disclosure. On September 9, 2024, Galectin Therapeutics Inc. (the "Company") is making its updated corporate presentation available on its website. The Company intends to use the presentation at conferences and meetings with investors, shareholders and analysts. A copy of the presentation is furnished herewith as Exhibit 99.1 and incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information furnished under this Item 7.01 of this Current Report on Form 8-K and the exhibits attached hereto are deemed to be "furnished" and shall not be deemed "filed" for the purpose of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall such information and exhibits be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended. This Current Report on Form 8-K and Exhibit 99.1 hereto contain forward-looking statements within the meaning of the federal securities laws. These forward-looking statements are based on current expectations and are not guarantees of future performance. Further, the forward-looking statements are subject to the limitations listed in Exhibit 99.1 and in the other reports of the Company filed with the Securities and Exchange Commission, including that actual events or results may differ materially from those in the forward-looking statements.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Exhibit Description 99.1 Galectin Therapeutic Inc. Corporate Presentation, updated September 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) - 2 -

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, Galectin Therapeutics Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Galectin Therapeutics Inc. Date: September 9, 2024 By: /s/ Jack W. Callicutt Jack W. Callicutt Chief Financial Officer - 3 -

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing